https://www.thepharmaletter.comRSS for NodeTue, 28 Apr 2026 22:48:33 GMThttps://www.thepharmaletter.com/biotech-news/updated-eu-safety-info-for-yescarta-and-tecartushttps://www.thepharmaletter.com/biotech-news/updated-eu-safety-info-for-yescarta-and-tecartusTue, 28 Apr 2026 17:42:16 GMThttps://www.thepharmaletter.com/biotech-news/mbiomics-series-a-to-turn-microbiome-science-into-scalable-therapeutic-approachhttps://www.thepharmaletter.com/biotech-news/mbiomics-series-a-to-turn-microbiome-science-into-scalable-therapeutic-approachTue, 28 Apr 2026 16:29:35 GMThttps://www.thepharmaletter.com/pharma-news/astrazeneca-s-breztri-approved-in-usa-for-asthmahttps://www.thepharmaletter.com/pharma-news/astrazeneca-s-breztri-approved-in-usa-for-asthmaTue, 28 Apr 2026 15:05:55 GMThttps://www.thepharmaletter.com/biotech-news/immunic-appoints-michael-panzara-as-cmohttps://www.thepharmaletter.com/biotech-news/immunic-appoints-michael-panzara-as-cmoTue, 28 Apr 2026 14:22:59 GMThttps://www.thepharmaletter.com/profluent-inks-strategic-ai-partnership-with-lillyhttps://www.thepharmaletter.com/profluent-inks-strategic-ai-partnership-with-lillyTue, 28 Apr 2026 13:36:56 GMThttps://www.thepharmaletter.com/biotech-news/intellia-announces-crispr-breakthrough-and-filinghttps://www.thepharmaletter.com/biotech-news/intellia-announces-crispr-breakthrough-and-filingTue, 28 Apr 2026 13:34:09 GMThttps://www.thepharmaletter.com/biotech-news/ligand-to-acquire-xoma-royaltyhttps://www.thepharmaletter.com/biotech-news/ligand-to-acquire-xoma-royaltyTue, 28 Apr 2026 12:55:03 GMThttps://www.thepharmaletter.com/biotech-news/sobi-1st-qtr-2026-report-sees-24-percent-revenue-boosthttps://www.thepharmaletter.com/biotech-news/sobi-1st-qtr-2026-report-sees-24-percent-revenue-boostTue, 28 Apr 2026 11:21:38 GMThttps://www.thepharmaletter.com/biotech-news/quviviq-keeps-idorsia-on-trackhttps://www.thepharmaletter.com/biotech-news/quviviq-keeps-idorsia-on-trackTue, 28 Apr 2026 11:20:47 GMThttps://www.thepharmaletter.com/pharma-news/opportunities-arising-from-uk-clinical-trials-reform-a-legal-viewhttps://www.thepharmaletter.com/pharma-news/opportunities-arising-from-uk-clinical-trials-reform-a-legal-viewTue, 28 Apr 2026 10:13:22 GMThttps://www.thepharmaletter.com/pharma-news/compass-drug-shows-mixed-latestage-results-shares-slidehttps://www.thepharmaletter.com/pharma-news/compass-drug-shows-mixed-latestage-results-shares-slideTue, 28 Apr 2026 09:40:52 GMThttps://www.thepharmaletter.com/pharma-news/rezzayo-phase-iii-data-puts-transplant-prevention-use-in-viewhttps://www.thepharmaletter.com/pharma-news/rezzayo-phase-iii-data-puts-transplant-prevention-use-in-viewTue, 28 Apr 2026 09:36:33 GMThttps://www.thepharmaletter.com/pharma-news/globaldata-flags-early-promise-for-cerevances-solengepras-in-parkinsonshttps://www.thepharmaletter.com/pharma-news/globaldata-flags-early-promise-for-cerevances-solengepras-in-parkinsonsTue, 28 Apr 2026 09:31:37 GMThttps://www.thepharmaletter.com/pharma-news/novartis-hit-by-generic-erosion-despite-strong-growth-from-newer-brandshttps://www.thepharmaletter.com/pharma-news/novartis-hit-by-generic-erosion-despite-strong-growth-from-newer-brandsTue, 28 Apr 2026 09:23:16 GMThttps://www.thepharmaletter.com/pharma-news/boehringer-s-survodutide-achieved-significant-weight-loss-of-16-percenthttps://www.thepharmaletter.com/pharma-news/boehringer-s-survodutide-achieved-significant-weight-loss-of-16-percentTue, 28 Apr 2026 08:43:58 GMThttps://www.thepharmaletter.com/pharma-news/aha-urges-hrsa-to-act-as-eli-lilly-threatens-340b-discounts-over-claims-data-submission-policyhttps://www.thepharmaletter.com/pharma-news/aha-urges-hrsa-to-act-as-eli-lilly-threatens-340b-discounts-over-claims-data-submission-policyTue, 28 Apr 2026 08:36:04 GMThttps://www.thepharmaletter.com/biotech-news/altimmune-secures-225-million-financing-for-pemvidutide-developmenthttps://www.thepharmaletter.com/biotech-news/altimmune-secures-225-million-financing-for-pemvidutide-developmentTue, 28 Apr 2026 07:42:48 GMThttps://www.thepharmaletter.com/pharma-news/veradermics-makes-gains-on-hair-loss-pill-datahttps://www.thepharmaletter.com/pharma-news/veradermics-makes-gains-on-hair-loss-pill-dataMon, 27 Apr 2026 15:11:40 GMThttps://www.thepharmaletter.com/biotech-news/oruka-therapeutics-leaps-on-positive-week-16-data-for-orka-001https://www.thepharmaletter.com/biotech-news/oruka-therapeutics-leaps-on-positive-week-16-data-for-orka-001Mon, 27 Apr 2026 15:11:11 GMThttps://www.thepharmaletter.com/biotech-news/lilly-to-acquire-ajax-therapeuticshttps://www.thepharmaletter.com/biotech-news/lilly-to-acquire-ajax-therapeuticsMon, 27 Apr 2026 14:31:10 GMT